NAS10026,630−6.36%S&P7,354−4.36%GOLD$4,058−1.34%BTC$75,641−0.40%VIX26.36−6.46%latest tape · as of 14:04 UTC
The Screen · Financials · Financial Data & Stock Exchanges
FactSet
FDS · a US exchange · USD · Market cap $11.7B · 12,840 employees
FactSet Research Systems Inc., together with its subsidiaries, operates as a financial digital platform and enterprise solutions provider for the investment community.
FAIL · Does not pass the screen
340.47 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 14:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price340.47 USD at the 5 Nov 2026 close
Our value readFair vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.25, read 2026-11-03
Ethical does not pass the values gate
Price340.47 USD
Fair value310.99
Ethical score10.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup259.97+31.0% to today ✓Distribution gives way to Markup after an 8% slide in 2 weeks
2026-09-24Read Distribution284.10+19.8% to today Markup gives way to Distribution after an 11% rise in 12 weeks
2026-07-02Read Markup255.62+33.2% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
FactSet holds its Markup at $340.47. Consolidating, no directional conviction, held for 5 days.
As held on the ledger · 2026-11-05
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 5 days
Price at the screen
$340.47
Valuation
22.83 trailing · 15.30 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.70
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
FactSet does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when FDS's ethical verdict changes
Today FDS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades above our $310.99 fair value estimate, strong competitive moat, 6.30% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. The price runs 9.5% above the base estimate.
Where our models see it going: fair-value estimate $310.99, with a range of $244.48 to $407.47, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Data platform trips on ethics test
Every fund manager tapping a terminal for clean company data or portfolio numbers relies on a handful of specialist platforms that sit between raw filings and real decisions. FactSet built one of the stronger ones, with a genuine moat, 27 percent ROE, and 23 percent margins that most software names would envy. Yet the numbers still point to a pass.
We are staying away first because the business fails our ethical screen on activity grounds. That screen exists for exactly these cases, and no amount of operational quality overrides it. The modest 5 percent margin of safety at the current price and the 6 percent revenue growth simply do not change the call.
Analysts already see limited upside, with a median target below the current level and a hold rating across the board. Forward earnings sit at 13 times, which looks reasonable until you remember the ethical red line sits in front of any valuation debate. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
FDS trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$329.57+8.7%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 8.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 29% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $281.
2026-10-25Markup$303.21+4.3%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $280.
2026-10-18Markup$290.82+11.9%Entry 9
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 11.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $280.
2026-10-11Markup · changed$259.97+0.0%Entry 8
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $278.
2026-10-02Distribution$259.97-8.5%Entry 7
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 8.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $275. Since the last review it its composite score rose.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $270. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-29Markup$305.31+18.3%Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $255.
2026-07-28Markup$258.09+1.0%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $248.
2026-07-18Markup$255.62+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 41%. Our forward projection puts the odds of a 10% gain over the next month near 11%. The street (16 analysts) rates it hold, with a mean price target of $248.
2026-07-03Markup$255.62+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
